Repository logo
 

Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Hyperlipidaemia is a major risk factor of atherosclerotic cardiovascular disease (ASCVD). Risk of cardiovascular events depends on cumulative lifetime exposure to low-density lipoprotein cholesterol (LDL-C) and, independently, on the time course of exposure to LDL-C, with early exposure being associated with a higher risk1. Furthermore, LDL-C fluctuations are associated with ASCVD outcomes2–4. However, the precise mechanisms behind this increased ASCVD risk are not understood. Here we find that early intermittent feeding of mice on a high-cholesterol Western-type diet (WD) accelerates atherosclerosis compared with late continuous exposure to the WD, despite similar cumulative circulating LDL-C levels. We find that early intermittent hyperlipidaemia alters the number and homeostatic phenotype of resident-like arterial macrophages. Macrophage genes with altered expression are enriched for genes linked to human ASCVD in genome-wide association studies. We show that LYVE1+ resident macrophages are atheroprotective, and identify biological pathways related to actin filament organization, of which alteration accelerates atherosclerosis. Using the Young Finns Study, we show that exposure to cholesterol early in life is significantly associated with the incidence and size of carotid atherosclerotic plaques in mid-adulthood. In summary, our results identify early intermittent exposure to cholesterol as a strong determinant of accelerated atherosclerosis, highlighting the importance of optimal control of hyperlipidaemia early in life, and providing insights into the underlying biological mechanisms. This knowledge will be essential to designing effective therapeutic strategies to combat ASCVD.

Description

Acknowledgements: Z.M. is supported by a BHF chair grant (CH/10/001/27642), a BHF Special Project Grant (SP/F/20/150010), the BHF Centre of Research Excellence (RE/18/1/34212), the Leducq Foundation (20CVD03) and the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care; M.N. by a BHF Intermediate Fellowship (G103314). S.A.N. is supported by a BHF Project Grant (PG/21/10816); and T.X.Z. through the BHF (CH/10/001/27642) and by the BMA Foundation, and the Academy of Medical Sciences (SGL025/1071). This work is also supported by a NMRC-funded grant to H.Y.L. (OFYIRG20nov-0013) and to V.A. (OF-IRG19Nov-0112). J.W.W. and P.R.S. were supported by the American Heart Association (CDA855022) and the US National Institutes of Health (R01 AI165553); D.T. by the European Research Council (ERC Starting grant), the Austrian Science Fund (I4963, P35233) and the European Research Area Network on Cardiovascular Diseases (I4647); F.S. by the German Research Foundation (DFG) through the grant SO1141/10-1 and the Research Unit FOR5042 “miTarget—The Microbiome as a Target in Inflammatory Bowel Diseases” (project P5); S.K.M. through a Corona Foundation grant (S199/10087/2022), and a DFG grant (SFB 1123/Z1); and C.R. by a Wellcome Investigator Award (095623/Z/11/Z). This work is also supported by the Academy of Finland (grant numbers 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi) and 41071 (Skidi)); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant number X51001); the Turku University Foundation; Tampere University Hospital Supporting Foundation; the Juho Vainio Foundation; Paavo Nurmi Foundation; the Finnish Foundation of Cardiovascular Research; Orion-Farmos Research Foundation; Sigrid Juselius Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; Tampere Tuberculosis Foundation; the Finnish Cultural Foundation; and EU Horizon 2020 (grant number 755320 for TAXINOMISIS). J.S.K. is supported by the European Research Council (grant number 742927 for MULTIEPIGEN project), Maud Kuistila Memorial Foundation, Päivikki and Sakari Sohlberg Foundation, Finnish Medical Foundation, Paulon Foundation and Licentiate of Medicine Paavo Ilmari Ahvenainen Foundation; and C.G.M. by a National Health and Medical Research Council (NHMRC) Investigator Grant (APP1176494). The contents of the published material are solely the responsibility of the individual authors and do not reflect the views of the NHMRC. We thank W. Ise for his contribution to generating the Spicflox/flox mice; J.-B. Michel for providing tissue sections of healthy and atherosclerotic human coronary arteries; D. Cuchet-Lourenco and E. F. Warner for providing Jurkat cells and assistance with BMDM experiments, respectively; the staff at the Phenotyping Hub and Biochemical Assay Laboratory of Cambridge University Hospitals, the University of Cambridge Biomedical Services at the Anne McLaren Building, the Cancer Research UK Cambridge Institute Genomics Core facility and the Genomics & Bioinformatics Core, Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, University of Cambridge; the members of the Advanced Imaging and Histology cores of Life Sciences Institute, NUS; and S. U. Gan and S. K. Chuan for providing AAV8-D377Y-mPCSK9.

Keywords

Journal Title

Nature

Conference Name

Journal ISSN

0028-0836
1476-4687

Volume Title

634

Publisher

Nature Publishing Group UK

Rights and licensing

Except where otherwised noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/